ANEUVO
Los Angeles
About ANEUVO
ANEUVO® is a platform and therapy development company focused on treating disabling injuries and disorders that have not been treated successfully with existing conventional therapies. Our mission is simple: help people living with SCI regain movement, independence, and hope. Spinal cord injuries present life-changing challenges, but innovative therapies like transcutaneous spinal stimulation are opening new doors. At ANEUVO, we share a common goal: to help restore functional independence, improve quality of life, and create a healthier, more equitable world for people living with disabling diseases and conditions. The ANEUVO ExaStim® Stimulation System is an FDA Breakthrough Device Designated non-invasive neuromodulation system created by ANEUVO for the treatment of spinal cord injury. The system recently received CE Mark approval in April of 2025.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $23.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2026)
- Website: aneuvo.com
- Phone: (424) 256-2194
Industries & Categories
Biotechnology, Health Care, Life Science, Medical Device, Rehabilitation
Social Profiles
Canonical: https://fsome.com/organization/aneuvo-126303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.